Tetracycline

Generic Name
Tetracycline
Brand Names
Pylera, Sumycin
Drug Type
Small Molecule
Chemical Formula
C22H24N2O8
CAS Number
60-54-8
Unique Ingredient Identifier
F8VB5M810T
Background

Tetracycline is a broad spectrum polyketide antibiotic produced by the Streptomyces genus of Actinobacteria. It exerts a bacteriostatic effect on bacteria by binding reversible to the bacterial 30S ribosomal subunit and blocking incoming aminoacyl tRNA from binding to the ribosome acceptor site. It also binds to some extent to the bacterial 50S ribosomal sub...

Indication

Used to treat bacterial infections such as Rocky Mountain spotted fever, typhus fever, tick fevers, Q fever, rickettsialpox and Brill-Zinsser disease. May be used to treat infections caused by Chlamydiae spp., B. burgdorferi (Lyme disease), and upper respiratory infections caused by typical (S. pneumoniae, H. influenzae, and M. catarrhalis) and atypical orga...

Associated Conditions
Acinetobacter Infections, Actinomycosis, Anthrax, Bacterial Infections, Bartonellosis, Brucellosis, Campylobacter Infection, Chancroid, Chlamydial Infections, Cholera (Disorder), Clostridium Infections, Conjunctivitis, Inclusion, Cystitis, Endometritis, Entamoebic histolytica infection, Escherichia infections, Granuloma Inguinale, Helicobacter Pylori Infection, Infection, Infection, Bacteroides, Klebsiella Infections, Listeria infection, Lower respiratory tract infection bacterial, Lymphogranuloma Venereum, Necrotizing ulcerative gingivostomatitis, Neisseria Gonorrhoeae Infection, Nephritis, Ornithosis, Plague, Prostatitis, Psittacosis, Q Fever, Relapsing Fever, Rickettsialpox, Rocky Mountain Spotted Fever, Rosacea, Severe Acne, Shigella Infection, Skin Infections caused by Staphylococcus Aureus, Skin and Subcutaneous Tissue Bacterial Infections, Syphilis, Trachoma, Tularemia, Typhus, Upper respiratory tract infection bacterial, Urinary Tract Infection, Yaws, Grade 1, grade 2, grade 3, grade 4 Urinary Tract Infection
Associated Therapies
-

Compare Sequential and Quadruple Therapy for the Eradication of Helicobacter Pylori in Korea

First Posted Date
2014-06-10
Last Posted Date
2019-05-13
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
390
Registration Number
NCT02159976
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam-si, Gyeonggi-do, Korea, Republic of

Tetracycline as a Prophylaxis for Rash in Patients With NSCLC Receiving Treatment With BIBW2992 (Afatinib)

Phase 2
Completed
Conditions
Interventions
First Posted Date
2013-06-19
Last Posted Date
2023-05-23
Lead Sponsor
Instituto Nacional de Cancerologia de Mexico
Target Recruit Count
107
Registration Number
NCT01880515
Locations
🇲🇽

Instituto Nacional de Cancerología, Mexico City, Mexico

Long-term Follow up Helicobacter Pylori Reinfection Rate After Second-Line Treatment: Bismuth-Containing Quadruple Therapy Versus Moxifloxacin-Based Triple Therapy

First Posted Date
2013-02-15
Last Posted Date
2013-02-15
Lead Sponsor
Seoul National University Bundang Hospital
Target Recruit Count
648
Registration Number
NCT01792700
Locations
🇰🇷

Seoul National University Bundang Hospital, Seongnam, Gyeonggi-do, Korea, Republic of

Intralesional Tetracycline Injection in the Treatment of Chalazia

Early Phase 1
Withdrawn
Conditions
Interventions
First Posted Date
2013-01-08
Last Posted Date
2017-01-12
Lead Sponsor
The Cleveland Clinic
Registration Number
NCT01763437
Locations
🇺🇸

Cleveland Clinic Cole Eye Institute, Cleveland, Ohio, United States

Effects of Teriparatide or Denosumab on Bone in Postmenopausal Women With Osteoporosis

First Posted Date
2012-12-20
Last Posted Date
2015-10-08
Lead Sponsor
Eli Lilly and Company
Target Recruit Count
69
Registration Number
NCT01753856
Locations
🇨🇦

For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician., Sainte-Foy, Quebec, Canada

Levofloxacin and Bismuth-containing Therapy Versus Quadruple Therapy as Second-line Treatment of Resistant Helicobacter Pylori Infection

First Posted Date
2012-12-05
Last Posted Date
2014-08-29
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
200
Registration Number
NCT01742429
Locations
🇨🇳

Renji Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, Shanghai, China

Empirical Rescue Therapies of Helicobacter Pylori Infection

First Posted Date
2012-08-20
Last Posted Date
2013-06-04
Lead Sponsor
Shanghai Jiao Tong University School of Medicine
Target Recruit Count
424
Registration Number
NCT01668927
Locations
🇨🇳

Renji Hospital, Shanghai, Shanghai, China

S0307A, Long-Term Bone Quality in Women With Breast Cancer Enrolled on Clinical Trial SWOG-S0307

Withdrawn
Conditions
First Posted Date
2009-04-02
Last Posted Date
2013-04-10
Lead Sponsor
SWOG Cancer Research Network
Registration Number
NCT00873808
Locations
🇺🇸

University Cancer Center at University of Washington Medical Center, Seattle, Washington, United States

Comparison of 7-day and 14-day Bismuth Based Quadruple Therapy for Secondary Helicobacter Pylori Eradication

First Posted Date
2009-02-11
Last Posted Date
2016-12-06
Lead Sponsor
Asan Medical Center
Target Recruit Count
199
Registration Number
NCT00841854
Locations
🇰🇷

Asan Medical Center, Seoul, Korea, Republic of

Bone Disease in Severely Burned Children

First Posted Date
2008-01-11
Last Posted Date
2014-06-06
Lead Sponsor
The University of Texas Medical Branch, Galveston
Target Recruit Count
254
Registration Number
NCT00591162
Locations
🇺🇸

U.T.M.B., Galveston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath